Search results for " Survival Rate"

showing 10 items of 63 documents

Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell su…

2008

Background We evaluated an intensified chemotherapy strategy in children with Wilms tumor who relapsed with high-risk features. Procedures From January 2001 to June 2006, we treated 20 consecutive children with reinduction chemotherapy (using ifosfamide/carboplatin/etoposide in 15/20 cases), with (n = 15) or without (n = 5) subsequent high-dose chemotherapy and hematopoietic stem cell support, surgery where feasible, and radiation therapy. The median time to relapse was 10 months after nephrectomy. All but two children initially received doxorubicin as first-line therapy. Results All patients were assessed for outcome: 13 are currently alive, 12 of them in remission a median 25 months since…

OncologyMaleTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantationNephrectomyPediatricschemistry.chemical_compoundHigh-dose chemotherapyRelapseChildIfosfamideGraft SurvivalRemission InductionHematopoietic Stem Cell TransplantationHematologyPerinatology and Child HealthSurvival RateTreatment OutcomeItalyOncologyChild PreschoolAbsolute neutrophil countFemaleAutologousmedicine.drugmedicine.medical_specialtyAntineoplastic AgentsTransplantation AutologousWilms TumorInternal medicinemedicineHumansPreschoolSurvival rateSalvage TherapyChemotherapyTransplantationbusiness.industryInfantWilms' tumormedicine.diseaseCarboplatinSurgeryRadiation therapychemistryPediatrics Perinatology and Child HealthAutologous hematopoietic stem cell transplantation; High-dose chemotherapy; Relapse; Wilms tumor; Antineoplastic Agents; Child; Child Preschool; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Italy; Male; Nephrectomy; Remission Induction; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation Autologous; Treatment Outcome; Wilms Tumor; Pediatrics Perinatology and Child Health; Hematology; OncologybusinessAutologous hematopoietic stem cell transplantation
researchProduct

Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experienc…

2020

Background Malignant germ cell tumors (GCTs) are a heterogeneous group of rare neoplasms in children. Optimal outcome is achieved with multimodal therapies for patients with both localized and advanced disease, especially after the introduction of platinum-based chemotherapy regimens. In this respect, data on salvage treatment for children with relapsed or platinum-refractory disease are still limited. Methods Retrospective analysis of data regarding patients affected by malignant GCTs with platinum-refractory or relapsed disease after first-line treatment according to AIEOP TCGM 2004 protocol was conducted. Results Twenty-one patients, 15 females and 6 males, were considered for the analys…

OncologyMelphalanMalemedicine.medical_treatmentDrug ResistanceSalvage therapyrelapsed tumorsDeoxycytidineCarboplatinchemistry.chemical_compound0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy Protocolsgerm cell tumorsChildEtoposideIfosfamideRemission InductionHematologyNeoplasms Germ Cell and EmbryonalPrognosisgerm cell tumors; high-dose chemotherapy; pediatric tumors; refractory tumors; relapsed tumors; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child Preschool; Cisplatin; Deoxycytidine; Drug Resistance Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence Local; Neoplasms Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Salvage Therapypediatric tumorsOxaliplatinSurvival RateLocalOncology030220 oncology & carcinogenesisChild PreschoolFemalerefractory tumorsmedicine.drugmedicine.medical_specialtyAdolescentPaclitaxelThioTEPA03 medical and health sciencesInternal medicinemedicineHumansIfosfamidePreschoolSurvival rateRetrospective StudiesSalvage TherapyChemotherapybusiness.industryInfantmedicine.diseaseGemcitabineCarboplatinNeoplasm RecurrencechemistryDrug Resistance NeoplasmPediatrics Perinatology and Child HealthSettore MED/20NeoplasmGerm Cell and EmbryonalGerm cell tumorsCisplatinNeoplasm Recurrence Localbusinesshigh-dose chemotherapy030215 immunologyFollow-Up StudiesPediatric bloodcancerREFERENCES
researchProduct

Mesenteric Lymph Node Involvement in Advanced Ovarian Cancer Patients Undergoing Rectosigmoid Resection: Prognostic Role and Clinical Considerations

2014

Background: The aim of this retrospective study was to investigate the incidence of mesenteric lymph node (MLN) involvement, and its prognostic role in advanced ovarian cancer (OC). Methods: OC patients undergoing rectosigmoid resection during primary debulking surgery or interval debulking surgery were recorded. Progression-free survival (PFS) and overall survival were calculated from the date of diagnosis to the date of relapse/progression, death of disease, or the date of last follow-up. Results: MLNs were detected in 102/148 cases (68.9 %); the rate of MLN involvement was 47.0 %. The percentage of metastatic MLNs was higher in cases with >5 MLNs removed compared with cases with ≤5 MLNs …

OncologySettore MED/18 - CHIRURGIA GENERALEGastroenterologyClear CellSurgical oncology80 and overMucinousMesenteryCystadenocarcinomaLymph nodeAged 80 and overOvarian NeoplasmsMedicine (all)Middle AgedDebulkingPrognosisAdenocarcinoma MucinousOVARIAN CANCERSurvival Ratemedicine.anatomical_structureOncologyLymphatic MetastasisAdenocarcinomaFemaleAdultmedicine.medical_specialtyCystadenocarcinomaAdenocarcinomaAdenocarcinoma Clear Cell; Adenocarcinoma Mucinous; Adult; Aged; Aged 80 and over; Cystadenocarcinoma Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mesentery; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Prognosis; Rectum; Retrospective Studies; Sigmoid Neoplasms; Survival Rate; Surgery; OncologyInternal medicinemedicineHumansSurvival rateAgedRetrospective Studiesbusiness.industryRectumSerousRetrospective cohort studymedicine.diseaseCystadenocarcinoma SerousEndometrial NeoplasmsSigmoid NeoplasmsSettore MED/40 - GINECOLOGIA E OSTETRICIALymph Node ExcisionSurgeryLymph NodesNeoplasm GradingOvarian cancerbusinessAdenocarcinoma Clear CellFollow-Up Studies
researchProduct

Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review.

2014

Abstract Background/objectives Cachexia affects ∼80% of pancreatic cancer patients. An international consensus defines cachexia as an ongoing loss of skeletal muscle mass (sarcopenia) with or without loss of fat, which impairs body functioning and cannot be reversed by conventional nutritional measures. Weight loss percentage and elevated inflammation markers have been employed to define this condition earlier. This review aimed to assess the prevalence and consequences of cachexia and sarcopenia on survival in patients with pancreatic ductal adenocarcinoma. Methods The systematic review was performed by searching the articles with preset terms published in PubMed and Cochrane Database unti…

Oncologymedicine.medical_specialtySarcopeniaCachexiaEndocrinology Diabetes and MetabolismOverweightCachexiaWeight lossInternal medicinePancreatic cancerWeight LossmedicinePrevalenceHumansSarcopenic obesityHepatologybusiness.industryConfoundingGastroenterologymedicine.diseasePrognosismusculoskeletal systemPancreatic NeoplasmsSurvival RateCachexia/diagnosis/epidemiology/*etiology; Carcinoma Pancreatic Ductal/*complications/mortality; Humans; Pancreatic Neoplasms/*complications/mortality; Prevalence; Prognosis; Sarcopenia/diagnosis/epidemiology/*etiology; Survival Rate; Weight LossSarcopeniaAdenocarcinomamedicine.symptombusinessCarcinoma Pancreatic Ductal
researchProduct

Collected World Experience About the Performance of the Snorkel/Chimney Endovascular Technique in the Treatment of Complex Aortic Pathologies

2015

OBJECTIVES: We sought to analyze the collected worldwide experience with use of snorkel/chimney endovascular aneurysm repair (EVAR) for complex abdominal aneurysm treatment. BACKGROUND: EVAR has largely replaced open surgery worldwide for anatomically suitable aortic aneurysms. Lack of availability of fenestrated and branched devices has encouraged an alternative strategy utilizing parallel or snorkel/chimney grafts (ch-EVAR). METHODS: Clinical and radiographic information was retrospectively reviewed and analyzed on 517 patients treated by ch-EVAR from 2008 from 2014 by prearranged defined and documented protocols. RESULTS: A total of 119 patients in US centers and 398 in European centers …

RegistrieMalemedicine.medical_treatmentKaplan-Meier EstimateGlobal HealthSettore MED/22 - Chirurgia VascolareSeverity of Illness IndexEndovascular aneurysm repairAortic aneurysmRetrospective StudieStentRegistriesAbdominal aortic aneurysm; Endovascular; Fenestrated; Thoracoabdominal; Vascular; Aortic Aneurysm Abdominal; Aortography; Blood Vessel Prosthesis Implantation; Endovascular Procedures; Europe; Female; Follow-Up Studies; Global Health; Humans; Kaplan-Meier Estimate; Male; Prosthesis Design; Prosthesis Failure; Retrospective Studies; Risk Assessment; Severity of Illness Index; Stents; Survival Rate; Treatment Outcome; United States; Blood Vessel Prosthesis; RegistriesEndovascularmedicine.diagnostic_testMedicine (all)Endovascular ProceduresAbdominal aortic aneurysmAortic AneurysmProsthesis FailureEuropeSurvival RateBlood Vessel ProsthesiTreatment OutcomeFemaleStentsHumanUnited Statemedicine.medical_specialtyAortographyProsthesis DesignAortographyRisk AssessmentFenestratedFollow-Up StudieBlood Vessel Prosthesis ImplantationBlood vessel prosthesisVascularmedicineHumansAbdominalSurvival rateRetrospective StudiesEndovascular Procedurebusiness.industryRetrospective cohort studymedicine.diseaseUnited StatesBlood Vessel ProsthesisSurgeryAbdominal aortic aneurysm; Endovascular; Fenestrated; Thoracoabdominal; Vascular; Aortic Aneurysm Abdominal; Aortography; Blood Vessel Prosthesis Implantation; Endovascular Procedures; Europe; Female; Follow-Up Studies; Global Health; Humans; Kaplan-Meier Estimate; Male; Prosthesis Design; Prosthesis Failure; Retrospective Studies; Risk Assessment; Severity of Illness Index; Stents; Survival Rate; Treatment Outcome; United States; Blood Vessel Prosthesis; Registries; Surgery; Medicine (all)Abdominal aortic aneurysmSurgeryThoracoabdominalbusinessAortic Aneurysm AbdominalFollow-Up StudiesAbdominal surgeryAnnals of Surgery
researchProduct

Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials

2019

Aim: To benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using individual participant survival data, and to meta-analyze prognostic factors for OS and TTP. Methods: RCTs were identified through literature search until December 2018. Individual participant survival was reconstructed with an algorithm from published Kaplan–Meier curves. Results: Ten RCTs were included. Median OS was 10.0 months (95% CI: 9.6–10.5), and median TTP was 4.1 months (95% CI: 3.8–4.3). Multivariable analyses showed HCV positivity, absence of macrovascular invasion and extra-…

SorafenibOncologyCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularPhase iii trialsAntineoplastic AgentsDiseasesurvivaltime to progressionSystemic therapysystemic therapylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemeta-regressionmedicineHumansClinical TrialsMeta-regressionbusiness.industryCarcinomaLiver NeoplasmsHepatocellularhepatocellular carcinomaGeneral MedicineSorafenibmedicine.diseasePhase III as TopicSurvival RateTreatment Outcomehepatocellular carcinoma; meta-regression; sorafenib; survival; systemic therapy; time to progression; Antineoplastic Agents; Carcinoma Hepatocellular; Clinical Trials Phase III as Topic; Humans; Liver Neoplasms; Sorafenib; Survival Rate; Treatment OutcomeClinical Trials Phase III as TopicOncology030220 oncology & carcinogenesisHepatocellular carcinomaMeta-analysissorafenib030211 gastroenterology & hepatologybusinessmedicine.drug
researchProduct

Robotic versus laparoscopic radical hysterectomy in early cervical cancer: A case matched control study

2018

Abstract Background This study aims at evaluating the feasibility, surgical outcome and oncological results observed after robotic radical hysterectomy (RH) compared to laparoscopy for patients with early stage cervical cancer (ECC) patients. Methods Between January 2010 and October 2016, 210 patients underwent RH for treatment of ECC: 70 underwent robotic approach (Cases), and 140 underwent laparoscopic approach (Controls). Results There was no statistically significant difference between the two approaches with regard to clinical patient characteristics and in terms of extent of RH and rate of pelvic and aortic lymphadenectomy. Operative time was significantly longer in the robotic versus…

Uterine Cervical NeoplasmTime Factorsmedicine.medical_treatmentEarly stage cervical cancerUterine Cervical Neoplasms0302 clinical medicinePostoperative ComplicationsRetrospective StudieLaparotomy80 and overMedicineEarly Detection of CancerEarly stage cervical cancer; Laparoscopy; Robotic surgery; Adult; Aged; Aged 80 and over; Female; Humans; Hysterectomy; Incidence; Italy; Laparoscopy; Middle Aged; Postoperative Complications; Retrospective Studies; Robotics; Survival Rate; Time Factors; Uterine Cervical Neoplasms; Young Adult; Early Detection of Cancer; Neoplasm Staging; Surgery; OncologyAged 80 and over030219 obstetrics & reproductive medicineIncidenceGeneral MedicineRoboticsMiddle AgedSurvival RateOncologyItaly030220 oncology & carcinogenesisFemaleHumanAdultmedicine.medical_specialtyTime FactorHysterectomy03 medical and health sciencesYoung AdultHumansRobotic surgeryRadical surgeryRadical HysterectomySurvival rateRetrospective StudiesAgedNeoplasm StagingHysterectomybusiness.industryRobotic surgeryPerioperativeSurgeryRoboticSettore MED/40 - GINECOLOGIA E OSTETRICIASurgeryLymphadenectomyLaparoscopyPostoperative Complicationbusiness
researchProduct

Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy

2016

AbstractInactivation of p53 found in more than half of human cancers is often associated with increased tumor resistance to anti-cancer therapy. We have previously shown that overexpression of the phosphatase Wip1 in p53-negative tumors sensitizes them to chemotherapeutic agents, while protecting normal tissues from the side effects of anti-cancer treatment. In this study, we decided to search for kinases that prevent Wip1-mediated sensitization of cancer cells, thereby interfering with efficacy of genotoxic anti-cancer drugs. To this end, we performed a flow cytometry-based screening in order to identify kinases that regulated the levels of γH2AX, which were used as readout. Another criter…

Wip1ApoptosisCell Cycle ProteinsPharmacologyMESH: G2 Phase Cell Cycle CheckpointsHistonesMESH : PhosphorylationMiceMESH : Cell Cycle ProteinsMESH: AnimalsMESH: Tumor Suppressor Protein p53MESH: HistonesKinaseTp53 mutationsMESH : Mice Transgenic3. Good healthProtein Phosphatase 2CSurvival RateMESH : Antineoplastic AgentsH2ax phosphorylationP53 activationMESH: Protein Phosphatase 2CRNA InterferenceMESH : Colorectal NeoplasmsMESH : Carrier ProteinsHistone H2axMESH: MitochondriaImmunologyHuman fibroblastsMESH: Carrier ProteinsAntineoplastic AgentsMESH: Protein-Tyrosine KinasesMESH: Protein-Serine-Threonine KinasesMESH : Cisplatin03 medical and health sciencesMESH: Cell Cycle ProteinsGenotoxic stressMESH : Protein-Tyrosine KinasesHumansMESH : HistonesAnticancer TherapyMESH: DNA DamageCisplatinMESH: HumansMESH: Phosphorylation[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMESH : HumansMESH : Nuclear Proteins030104 developmental biologyCancer cellMESH: Antineoplastic AgentsCisplatinCarrier ProteinsMESH: Nuclear ProteinsMESH : ApoptosisDna-damage response0301 basic medicineCancer ResearchMESH: Caspase 3MESH : Caspase 3PhosphorylationCytotoxicityMESH : DNA DamageSensitizationmedicine.diagnostic_testCaspase 3Nuclear ProteinsProtein-Tyrosine KinasesMESH : Survival RateMitochondriaG2 Phase Cell Cycle CheckpointsWee1medicine.anatomical_structureMESH : Protein Phosphatase 2COriginal ArticleMESH : MitochondriaColorectal Neoplasmsmedicine.drugMESH : Protein-Serine-Threonine KinasesMESH: Cell Line TumorMESH: Survival RateMESH: Mice TransgenicMESH: RNA InterferencePhosphataseMice Transgenic[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiologyProtein Serine-Threonine KinasesFlow cytometryCellular and Molecular NeuroscienceCell Line TumorMESH : MicemedicineAnimalsMESH: MiceMESH : Cell Line TumorMESH: ApoptosisCell BiologyMESH : Tumor Suppressor Protein p53MESH: CisplatinCancer researchbiology.proteinMESH : AnimalsMESH : G2 Phase Cell Cycle CheckpointsMESH : RNA InterferenceTumor Suppressor Protein p53MESH: Colorectal NeoplasmsDNA DamageCell Death & Disease
researchProduct

Palliative sedation in advanced cancer patients followed at home: A retrospective analysis

2012

Abstract CONTEXT: Data regarding palliative sedation at home in dying patients are lacking. OBJECTIVES: To describe the frequency, indication, and modality of palliative sedation (PS) in patients followed at home. METHODS: A retrospective analysis of home care cancer patients was performed. Patients who received PS before dying were selected and information about epidemiologic characteristics, indications, duration, drugs, and outcomes was collected. RESULTS: Of 370 medical charts of patients who died at home, 49 patients received PS before dying. PS was proposed by the team, relatives, or both in 63.3%, 4.1%, and 32.6% of cases, respectively. Delirium alone or in combination with other sym…

end of lifeMalePediatricsmedicine.medical_specialtyPalliative carePainComorbiditySettore MED/42 - Igiene Generale E ApplicataPalliative sedationadvanced cancer patientPalliative sedationRisk FactorsNeoplasmsRETROSPECTIVE STUDYPrevalenceMedicineHumansHypnotics and SedativesPALLIATIVE SEDATION; advanced cancer patients; RETROSPECTIVE STUDYIntensive care medicineSurvival rateGeneral NursingSurvival analysisNursing (all)2901 Nursing (miscellaneous)Retrospective StudiesTerminal Carepalliative carebusiness.industryDeliriumRetrospective cohort studymedicine.diseaseComorbidityHome Care ServicesSurvival AnalysisSurvival RateTreatment OutcomeAnesthesiology and Pain MedicineItalyend of life; home care; palliative care; Palliative sedation; Comorbidity; Delirium; Female; Home Care Services; Humans; Hypnotics and Sedatives; Italy; Male; Neoplasms; Pain; Palliative Care; Prevalence; Retrospective Studies; Risk Factors; Survival Analysis; Survival Rate; Terminal Care; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)MidazolamDeliriumFemaleNeurology (clinical)medicine.symptombusinesshome caremedicine.drug
researchProduct

How to Ensure the Development of SMEs in Post-Pandemic Economy? A Start-ups Case Study

2023

Abstract After the humanitarian crisis, caused by COVID-19, enterprises have to face a post-pandemic economic crisis. As small and medium-sized enterprises (SMEs) constitute 99% of EU enterprises and create every third workplace (European Parliament, 2021), it is important to monitor their situation not only to survive but also to develop and build strong economies in the future. The aim of this research is to investigate development trends and opportunities in (SMEs’) development, with a special focus on start-ups (STPS) as representative of these. Also, special attention is paid to the concept of sustainable development (SD), which fulfils the UN 2030 Agenda for Sustainable Development Go…

enterprises survival ratestart-upsSMEssustainable development goalsTalTech Journal of European Studies
researchProduct